Home/Pipeline/XmAb®541

XmAb®541

Advanced Solid Tumors

Phase 1Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Active

Company

Xencor

About Xencor

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders Infectious Disease

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active